Development of biomarkers for Huntington's disease

Summary Huntington's disease is an autosomal dominant, progressive neurodegenerative disorder, for which there is no disease-modifying treatment. By use of predictive genetic testing, it is possible to identify individuals who carry the gene defect before the onset of symptoms, providing a wind...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2011-06, Vol.10 (6), p.573-590
Main Authors: Weir, David W, BSc, Sturrock, Aaron, MBBS, Leavitt, Blair R, MDCM
Format: Article
Language:English
Subjects:
Alzheimer's disease
Antioxidants - metabolism
Biomarkers
Biomarkers - metabolism
Brain - anatomy & histology
Brain - metabolism
Brain - pathology
Brain - physiopathology
Clinical trials
Diagnostic Imaging - methods
Disease Progression
Endocrine System - physiology
Genotype & phenotype
Humans
Huntington Disease - diagnosis
Huntington Disease - genetics
Huntington Disease - pathology
Huntington Disease - physiopathology
Huntingtons disease
Magnetic Resonance Imaging
Medical imaging
Mutation
Neurobiology
Neuroimaging
Neurology
Observational studies
Oxidative Stress
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Huntington's disease is an autosomal dominant, progressive neurodegenerative disorder, for which there is no disease-modifying treatment. By use of predictive genetic testing, it is possible to identify individuals who carry the gene defect before the onset of symptoms, providing a window of opportunity for intervention aimed at preventing or delaying disease onset. However, without robust and practical measures of disease progression (ie, biomarkers), the efficacy of therapeutic interventions in this premanifest Huntington's disease population cannot be readily assessed. Current progress in the development of biomarkers might enable evaluation of disease progression in individuals at the premanifest stage of the disease; these biomarkers could be useful in defining endpoints in clinical trials in this population. Clinical, cognitive, neuroimaging, and biochemical biomarkers are being investigated for their potential in clinical use and their value in the development of future treatments for patients with Huntington's disease.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(11)70070-9